BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 25606362)

  • 1. Modeling fragile X syndrome in the Fmr1 knockout mouse.
    Kazdoba TM; Leach PT; Silverman JL; Crawley JN
    Intractable Rare Dis Res; 2014 Nov; 3(4):118-33. PubMed ID: 25606362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
    Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
    PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome.
    Kalinowska M; van der Lei MB; Kitiashvili M; Mamcarz M; Oliveira MM; Longo F; Klann E
    Mol Autism; 2022 Jun; 13(1):29. PubMed ID: 35768828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins.
    Spencer CM; Serysheva E; Yuva-Paylor LA; Oostra BA; Nelson DL; Paylor R
    Hum Mol Genet; 2006 Jun; 15(12):1984-94. PubMed ID: 16675531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Biomarkers in Fragile X Syndrome.
    Zafarullah M; Tassone F
    Brain Sci; 2019 Apr; 9(5):. PubMed ID: 31035599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperexcitability in the Olfactory Bulb and Impaired Fine Odor Discrimination in the
    Kuruppath P; Xue L; Pouille F; Jones ST; Schoppa NE
    J Neurosci; 2023 Nov; 43(48):8243-8258. PubMed ID: 37788940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteome profiling of the prefrontal cortex of Fmr1 knockout mouse reveals enhancement of complement and coagulation cascades.
    Gao MM; Shi H; Yan HJ; Long YS
    J Proteomics; 2023 Mar; 274():104822. PubMed ID: 36646274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
    Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
    Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
    Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
    J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study.
    Jalnapurkar I; Frazier JA; Roth M; Cochran DM; Foley A; Merk T; Venuti L; Ronco L; Raines S; Cadavid D
    J Neurodev Disord; 2022 Dec; 14(1):57. PubMed ID: 36494616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau reduction attenuates autism-like features in Fmr1 knockout mice.
    Zhao S; Jiang X; Han L; Jiang Y; Wang Y; Meng J; Zhu X; Zhang X; Luo H; Zhang YW
    Mol Autism; 2023 Nov; 14(1):42. PubMed ID: 37936174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNAs and Fragile X Syndrome.
    Lin SL
    Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial FMRP expression is sufficient to normalize neuronal hyperactivity in Fragile X neurons.
    Graef JD; Wu H; Ng C; Sun C; Villegas V; Qadir D; Jesseman K; Warren ST; Jaenisch R; Cacace A; Wallace O
    Eur J Neurosci; 2020 May; 51(10):2143-2157. PubMed ID: 31880363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragile X Mental Retardation-1 Knockout Zebrafish Shows Precocious Development in Social Behavior.
    Wu YJ; Hsu MT; Ng MC; Amstislavskaya TG; Tikhonova MA; Yang YL; Lu KT
    Zebrafish; 2017 Oct; 14(5):438-443. PubMed ID: 28829283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragile X syndrome: From protein function to therapy.
    Bagni C; Oostra BA
    Am J Med Genet A; 2013 Nov; 161A(11):2809-21. PubMed ID: 24115651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
    Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
    Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
    Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
    Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic variability to medication management: an update on fragile X syndrome.
    Elhawary NA; AlJahdali IA; Abumansour IS; Azher ZA; Falemban AH; Madani WM; Alosaimi W; Alghamdi G; Sindi IA
    Hum Genomics; 2023 Jul; 17(1):60. PubMed ID: 37420260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling Fragile X Syndrome in
    Drozd M; Bardoni B; Capovilla M
    Front Mol Neurosci; 2018; 11():124. PubMed ID: 29713264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.